Epstein-Barr virus as a therapeutic target in Hodgkin's disease and nasopharyngeal carcinoma

Seminars in Cancer Biology

Volumn 7, Issue 4, 1996, Pages 217-226

  Ambinder, Richard F ^a   Robertson, Keith D ^a   Moore, Stacy M ^a   Yang, Jie ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

5 azacytidine; Bryostatin; Epstein barr virus; Hodgkin's disease; Nasopharyngeal carcinoma

Indexed keywords

GANCICLOVIR; PROTEIN KINASE C ACTIVATOR; THYMIDINE KINASE; VIRUS ANTIGEN;

ARTICLE; CYTOTOXIC T LYMPHOCYTE; DEMETHYLATION; EPSTEIN BARR VIRUS; HODGKIN DISEASE; HUMAN; NASOPHARYNX CARCINOMA; NONHUMAN;

EID: 0030221850     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1006/scbi.1996.0029     Document Type: Article

References (69)

1. 1. Bhatia S, Robison LL, Oberlin O, et al (1996) Breast cancer and other second neoplasms after childhood Hodgkin's disease. N Engl J Med 334:745-751
2. 2. Donaldson SS, Hancock SL (1996) Second cancers after Hodgkin's Disease in childhood. N Engl J Med 334:792-794
3. 3. Doria R, Holford T, Farber LR, Prosnitz LR, Cooper DL (1995) Second solid malignancies after combined modality therapy for Hodgkin's disease. J Clin Oncol 13:2016-2022
4. 4. Abrahamsen JF, Andersen A, Hannisdal E, et al (1993) Second malignancies after treatment of Hodgkin's disease: the influence of treatment, follow-up time, and age. J Clin Oncol 11:255-261
5. 5. Horning SJ, Adhikari A, Rizk N, Hoppe RT, Olshen RA (1994) Effect of treatment for Hodgkin's disease on pulmonary function: results of a prospective study. J Clin Oncol 12:297-305
6. 6. Van Hasselt CA, Gibb AG (1991) Nasopharyngeal Carcinoma. The Chinese University Press, Shatin, NT, Hong Kong
7. 7. Ambinder RF, Browning RJ, Lorenzana I, et al (1993) Epstein-Barr virus and childhood Hodgkin's disease in Honduras and the United States. Blood 81:462-467
8. 8. Armstrong AA, Alexander FE, Paes RP, et al (1993) Association of Epstein-Barr virus with pediatric Hodgkin's disease. Am J Pathol 142:1683-1688
9. 9. Chang KL, Albújar PF, Chen YY Johnson RM, Weiss LM (1993) High prevalence of Epstein-Barr virus in the Reed-Sternberg cells of Hodgkin's disease occurring in Peru. Blood 81:496-501
10. 10. Khan G, Norton AJ, Slavin G (1993) Epstein-Barr virus in Hodgkin's disease - relationship to age and subtype. Cancer 71:3124-3129
11. 11. Wu TC, Mann RB, Epstein J, et al (1991) Abundant expression of EBER1 small nuclear RNA in nasopharyngeal carcinoma: A morphologically distinctive target for detection of Epstein-Barr virus in formalin-fixed paraffin-embedded carcinoma specimens. Am J Pathol 138:1461-1469
12. 12. Pathmanathan R, Prasad U, Chandrika G, Sadler R, Flynn K, Raab-Traub N (1995) Undifferentiated, nonkeratinizing, and squamous cell carcinoma of the nasopharynx. Variants of Epstein-Barr virus-infected neoplasia. Am J Pathol 146:1355-1367
13. 13. Miller WE, Edwards RH, Walling DM, Raab-Traub N (1994) Sequence variation in the Epstein-Barr virus latent membrane protein 1. J Gen Virol 75:2729-2740
14. 14. Korbjuhn P, Anagnostopoulos I, Hummel M, et al (1993) Frequent latent Epstein-Barr virus infection of neoplastic T cells and bystander B cells in human immunodeficiency virus-negative European peripheral pleomorphic T-cell lymphomas. Blood 82:217-223
15. 15. Gulley ML, Eagan PA, Quintanilla-Martinez L, et al (1994) Epstein-Barr virus DNA is abundant and monoclonal in the Reed-Sternberg cells of Hodgkin's disease: association with mixed cellularity subtype and Hispanic American ethnicity. Blood 83:1595-1602
16. 16. Raab-Traub N, Flynn K (1986) The structure of the termini of the Epstein-Barr virus as a marker of clonal cellular proliferation. Cell 47:883-889
17. 17. Shimizu N, Tanabetochikura A, Kuroiwa Y, Takada K (1994) Isolation of Epstein-Barr virus (ebv)-negative cell clones from the EBV-positive Burkitts lymphoma (BL) line Akata - malignant phenotypes of BL cells are dependent on EBV. J Virol 68:6069-6073
18. 18. Gulley ML, Raphael M, Lutz CT, Ross DW, Raab-Traub N (1992) Epstein-Barr virus integration in human lymphomas and lymphoid cell lines. Cancer 70:185-191
19. 19. Yao QY, Rickinson AB, Epstein MA (1985) A re-examination of the Epstein-Barr virus carried state in healthy seropositive individuals. Int J Cancer 35:35-43
20. 20. Miyashita EM, Yang B, Lam KMC, Crawford DH, Thorley-Lawson DA (1995) A novel form of Epstein-Barr virus latency in normal B cells in vivo. Cell 80:593-601
21. 21. Ambinder RF, Wingard JR, Burns WH, et al (1985) Detection of Epstein-Barr virus DNA in mouth washes by hybridization. J Clin Microbiol 21:353-356
22. 22. Sixbey JW, Lemon SM, Pagano JS (1986) A second site for Epstein-Barr virus shedding: The uterine cervix. Lancet 2:1122-1124
23. 23. Sixbey JW, Nedrud JG, Raab-Traub N, Hanes RA, Pagano JS (1984) Epstein-Barr virus replication in oropharyngeal epithelial cells. N Engl J Med 310:1225-1230
24. 24. Allday MJ, Crawford DM (1988) Role of epithelium in EBV persistence and pathogenesis of B-cell tumours. Lancet 1:855-857
25. 25. Tao Q, Srivastava G, Chan AC, Chung LP, Loke SL, Ho FC (1995) Evidence for lytic infection by Epstein-Barr virus in mucosal lymphocytes instead of nasopharyngeal epithelial cells in normal individuals. J Med Virol 45:71-77
26. 26. De Souza YG, Greenspan D, Felton JR, Hartzog GA (1989) Localization of Epstein-Barr virus DNA in the epithelial cells of oral hairy leukoplakia by in situ hybridization on tissue sections. N Engl J Med 320:1559-1560
27. 27. Young LS, Lau R, Rowe M, et al (1991) Differentiation-associated expression of the Epstein-Barr virus BZLF1 transactivator protein in oral hairy leukoplakia. J Virol 65:2868-2874
28. 28. Lucas KG, Small TN, Heller G, Dupont B, O'Reilly RJ (1996) The development of cellular immunity to Epstein-Barr virus after allogeneic bone marrow transplantation. Blood 87:2594-2603
29. 29. Carmichael A, Jin X, Sissons P, Borysiewicz L (1993) Quantitative analysis of the human immunodeficiency virus type 1 (HIV-1)-specific cytotoxic T lymphocyte (CTL) response at different stages of HIV-1 infection: Differential CTL responses to HIV-1 and Epstein-Barr virus in late disease. J Exp Med 177:249-256
30. 30. Wang EC, Lehner PJ, Graham S, Borysiewicz LK (1994) CD8high (CD57+) T cells in normal, healthy individuals specifically suppress the generation of cytotoxic T lymphocytes to Epstein-Barr virus-transformed B cell lines. Eur J Immunol 24:2903-2909
31. 31. Swinnen LJ (1993) Transplant immunosuppression-related malignant lymphomas. Cancer Treat Res 66:95-110
32. 32. Papadopoulos EB, Ladanyi M, Emanuel D, et al (1994) Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 33:1185-1191
33. 33. Rooney CM, Smith CA, Ng CY, et al (1995) Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 345:9-13
34. 34. Young L, Alfieri C, Hennessy K, et al (1989) Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. N Engl J Med 321:1080-1085
35. 35. Delecluse HJ, Kremmer E, Rouault JP, Cour C, Bornkamm G, Berger F (1995) The expression of Epstein-Barr virus latent proteins is related to the pathological features of post-transplant lymphoproliferative disorders. Am J Pathol 146:1113-1120
36. 36. Khanna R, Burrows SR, Kurilla MG, et al (1992) Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: Implications for vaccine development. J Exp Med 176:169-176
37. 37. Murray RJ, Kurilla MG, Brooks JM, et al (1992) Identification of target antigens for the human cytotoxic T-cell response to Epstein-Barr virus (EBV): Implications for the immune control of EBV-positive malignancies. J Exp Med 176:157-168
38. 38. Deacon EM, Pallesen G, Niedobitek G, et al (1993) Epstein-Barr virus and Hodgkin's disease: Transcriptional analysis of virus latency in the malignant cells. J Exp Med 177:339-349
39. 39. Pallesen G, Hamilton-Dutoit SJ, Rowe M, Young LS (1991) Expression of Epstein-Barr virus (EBV) latent gene products in tumour cells of Hodgkin's disease. Lancet 337:320-322
40. 40. Grasser FA, Murray PG, Kremmer E, et al (1994) Monoclonal antibodies directed against the Epstein-Barr virus-encoded nuclear antigen 1 (EBNA1): immunohistologic detection of EBNA1 in the malignant cells of Hodgkin's disease. Blood 84:3792-3798
41. 41. Herbst H, Dallenbach F, Hummel M, et al (1991) Epstein-Barr virus latent membrane protein expression in Hodgkin and Reed-Sternberg cells. Proc Natl Acad Sci USA 88:4766-4770
42. 42. Levitskaya J, Coram M, Levitsky V, et al (1995) Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature 375:685-688
43. 43. Knecht H, Bachmann E, Brousset P, et al (1993) Deletions within the LMP1 oncogene of Epstein-Barr virus are clustered in Hodgkin's disease and identical to those observed in nasopharyngeal carcinoma. Blood 82:2937-2942
44. 44. Lee SP, Thomas WA, Murray RJ, et al (1993) HLA A2.1-restricted cytotoxic T cells recognizing a range of Epstein-Barr virus isolates through a defined epitope in latent membrane protein LMP2. J Virol 67:7428-7435
45. 45. Walter EA, Greenberg PD, Gilbert MJ, et al (1995) Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. New England Journal of Medicine 333:1038-1044
46. 46. Poppema S, Visser L (1994) Absence of HLA class I expression by Reed-Sternberg cells. Am J Pathol 145:37-41
47. 47. Oudejans JJ, Jiwa NM, Kummer JA, et al (1996) Analysis of major histocompatibility complex class I expression on Reed-Sternberg cells in relation to the cytotoxic T-cell response in Epstein-Barr virus-positive and -negative Hodgkin's disease. Blood 87:3844-3851
48. 48. Dolcetti R, Frisan T, Sjoberg J, et al (1995) Identification and characterization of an Epstein-Barr virus-specific T-cell response in the pathologic tissue of a patient with Hodgkin's disease Cancer Res 55:3675-3681
49. 49. Frisan T, Sjoberg J, Dolcetti R, et al (1995) Local suppression of Epstein-Barr virus (EBV)-specific cytotoxity in biopsies of EBV-positive Hodgkin's disease. Blood 86:1493-1501
50. 50. Poppema S, Visser L (1994) Epstein-Barr virus positivity in Hodgkin's disease does not correlate with an HLA A2-negative phenotype. Cancer 73:3059-3063
51. 51. Li-Fu H, Minarovits J, Shi-Long C, et al (1991) Variable expression of latent membrane protein in nasopharyngeal carcinoma can be related to methylation status of the Epstein-Barr virus BNLF-1 5′-flanking region. J Virol 65:1558-1567
52. 52. Hitt MM, Allday MJ, Kara T, et al (1989) EBV gene expression in an NPC-related tumour. EMBO J 8:2639-2651
53. 53. Fahraeus R, Fu HL, Ernberg I, et al (1988) Expression of Epstein-Barr virus-encoded proteins in nasopharyngeal carcinoma. Int J Cancer 42:329-338
54. 54. Young LS, Dawson CW, Clark D, et al (1988) Epstein-Barr virus gene expression in nasopharyngeal carcinoma. J Gen Virol 69:1051-1065
55. 55. Thomas JA, Iliescu V, Crawford DH, Ellouz R, Cammoun M, de-The G (1984) Expression of HLA-DR antigens in nasopharyngeal carcinoma: an immunohistological analysis of the tumour cells and infiltrating lymphocytes. Int J Cancer 33:813-819
56. 56. Sample J, Kieff E (1990) Transcription of the Epstein-Barr virus genome during latency in growth-transformed lymphocytes. J Virol 64:1667-1674
57. 57. Ling PD, Rawlins DR, Hayward SD (1993) The Epstein-Barr virus immortalizing protein EBNA-2 is targeted to DNA by a cellular enhancer-binding protein. Proc Natl Acad Sci USA 90:9237-9241
58. 58. Jin XW, Speck SH (1992) Identification of critical cis elements involved in mediating Epstein-Barr virus nuclear antigen 2-dependent activity of an enhancer located upstream of the viral BamHI C promoter. J Virol 66:2846-2852
59. 59. Woistschlaeger M, Jin XW, Yandava CN, Furmanski LA, Strominger JL, Speck SH (1991) Role for the Epstein-Barr virus nuclear antigen 2 in viral promoter switching during initial stages of infection. Proc Natl Acad Sci USA 88:3942-3946
60. 60. Robertson KD, Hayward DJ, Ling PD, Samid D, Ambinder RF (1995) Transcriptional activation of the EBV latency C promoter following 5-azacytidine treatment: Evidence that demethylation at a single CpG site is crucial. Mol Cell Biol 15:6150-6159
61. 61. Evans TJ, Jacquemin MG, Farrell PJ (1995) Efficient EBV superinfection of group I Burkitt's lymphoma cells distinguishes requirements for expression of the Cp viral promoter and can activate the EBV productive cycle. Virology 206:866-877
62. 62. Robertson KD, Manns A, Swinnen LJ, Zong JC, Gulley ML, Ambinder RF (1996) CpG methylation of the major Epstein-Barr virus latency promoter in Burkitt's lymphoma and Hodgkin's disease. Blood, in press
63. 63. Lowrey CH, Nienhuis AW (1993) Treatment with azacitidine of patients with end-stage β-thalassemia. N Engl J Med 329:845-848
64. 64. Charache S, Dover G, Smith K, Talbot CC, Jr, Moyer M, Boyer S (1983) Treatment of sickle cell anemia with 5-azacytidine results in increased fetal hemoglobin production and is associated with nonrandom hypomethylation of DNA around the gamma-delta-beta-globin gene complex. Proc Natl Acad Sci USA
65. 65. Bordignon C, Bonini C, Verzeletti S, et al (1995) Transfer of the HSV-tk gene into donor peripheral blood lymphocytes for in vivo modulation of donor anti-tumor immunity after allogeneic bone marrow transplantation. Hum Gene Ther 6:813-819
66. 66. Ilsley DD, Lee SH, Miller WH, Kuchta RD (1995) Acyclic guanosine analogs inhibit DNA polymerases alpha, delta, and epislon with very different potencies and have unique mechanisms of action. Biochemistry 34:2504-2510
67. 67. Leiden JM (1995) Gene therapy-promise, pitfalls, and prognosis. N Engl J Med 333:871-873
68. 68. Liebowitz D, Kieff E (1993) Epstein-Barr virus, in The Human Herpesviruses (Roizman B, Whitley RJ, Lopez C, eds) pp 107-172. Raven Press, New York
69. 69. Stewart JP, McGown AT, Prendiville J, Pettit GR, Fox BW, Arrand JR (1993) Bryostatin 1 induces productive Epstein-Barr virus replication in latently infected cells: implications for use in immunocomprised patients. Cancer Chemother Pharmacol 33:89-91